766 related articles for article (PubMed ID: 29182706)
1. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The "APOE4 Gene-Dose Effect".
Abushakra S; Porsteinsson A; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Hendrix S; Wang P; Shen L; Sampalis J; Tolar M
J Prev Alzheimers Dis; 2016; 3(4):219-228. PubMed ID: 29199323
[TBL] [Abstract][Full Text] [Related]
3. Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.
Kocis P; Tolar M; Yu J; Sinko W; Ray S; Blennow K; Fillit H; Hey JA
CNS Drugs; 2017 Jun; 31(6):495-509. PubMed ID: 28435985
[TBL] [Abstract][Full Text] [Related]
4. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.
Gauthier S; Aisen PS; Ferris SH; Saumier D; Duong A; Haine D; Garceau D; Suhy J; Oh J; Lau W; Sampalis J
J Nutr Health Aging; 2009 Jun; 13(6):550-7. PubMed ID: 19536424
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
6. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study.
Saumier D; Duong A; Haine D; Garceau D; Sampalis J
J Nutr Health Aging; 2009 Nov; 13(9):808-12. PubMed ID: 19812871
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M
CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
9. Tramiprosate.
Wright TM
Drugs Today (Barc); 2006 May; 42(5):291-8. PubMed ID: 16801992
[TBL] [Abstract][Full Text] [Related]
10. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
11. Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification.
Sabbagh MN
J Prev Alzheimers Dis; 2017; 4(3):136-137. PubMed ID: 29182703
[No Abstract] [Full Text] [Related]
12. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
13. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
[TBL] [Abstract][Full Text] [Related]
14. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
15. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
[TBL] [Abstract][Full Text] [Related]
16. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
[TBL] [Abstract][Full Text] [Related]
17. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).
Aisen PS; Gauthier S; Ferris SH; Saumier D; Haine D; Garceau D; Duong A; Suhy J; Oh J; Lau WC; Sampalis J
Arch Med Sci; 2011 Feb; 7(1):102-11. PubMed ID: 22291741
[TBL] [Abstract][Full Text] [Related]
18. Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
Hey JA; Abushakra S; Blennow K; Reiman EM; Hort J; Prins ND; Sheardova K; Kesslak P; Shen L; Zhu X; Albayrak A; Paul J; Schaefer JF; Power A; Tolar M
Drugs; 2024 Jun; ():. PubMed ID: 38902571
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
Grove RA; Harrington CM; Mahler A; Beresford I; Maruff P; Lowy MT; Nicholls AP; Boardley RL; Berges AC; Nathan PJ; Horrigan JP
Curr Alzheimer Res; 2014 Jan; 11(1):47-58. PubMed ID: 24359500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
